FDA clears blood test to aid evaluation for Alzheimer's disease

The U.S. Food and Drug Administration (FDA) has cleared an innovative humor trial for marketing. The test's underlying exertion was invented astatine Washington University School of Medicine successful St. Louis for the aboriginal diagnosis of Alzheimer's disease. The test, known arsenic PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup.